News room - Egetis Therapeutics

20 December, 2022 Egetis recruits Anny Bedard as President of Egetis North America News Corporate Information Staff change English IR Optional

7 December, 2022 Egetis submits Expanded Access Program for Emcitate® in the USA News Corporate Information Other Corporate Information English IR Optional

21 November, 2022 Egetis to participate at upcoming investor conferences News Corporate Information Other Corporate Information English IR Optional

18 November, 2022 Egetis continues to strengthen the commercial and medical affairs organizations for the expected launch of Emcitate® in 2024 News Corporate Information Other Corporate Information English IR Optional

8 November, 2022 Interim report January-September 2022 News English Regulatory MAR Report Interim Q3 IR Optional

25 October, 2022 Egetis presents Nomination Committee for the 2023 Annual General Meeting News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional

17 October, 2022 Egetis announces detailed design for small, randomized, placebo-controlled trial for Emcitate for US NDA submission News Corporate Information Other Corporate Information English IR Optional

13 October, 2022 Egetis presents significant progress towards market at Capital Markets Day today News Corporate Information Presentation English IR Optional

6 October, 2022 Egetis’ Capital Markets Day on October 13: Agenda and Registration Details News Corporate Information Other Corporate Information English IR Optional

30 August, 2022 Egetis to participate at upcoming medical conferences News Corporate Information Other Corporate Information English IR Optional

23 August, 2022 Egetis to participate at upcoming investor conferences News Corporate Information Other Corporate Information English IR Optional

19 August, 2022 Interim report Q2 2022 News English Regulatory MAR VPML Report Interim Q2 IR Optional

18 August, 2022 Save the Date: Egetis to host a Capital Markets Day in Stockholm on October 13, 2022 News Corporate Information Nomination Committee English IR Optional

10 August, 2022 Egetis establishes subsidiary in the United States News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate

13 July, 2022 Egetis receives positive opinion on orphan designation for Aladote® from the European Medicines Agency for the Prevention of Acute Liver Failure News Corporate Information Other Corporate Information English IR Optional mfn-cus-aladote

20 June, 2022 Egetis appoints Sara Melton as President of North America News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate

31 May, 2022 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional

30 May, 2022 Bulletin from Egetis Therapeutics’ Annual General Meeting 2022 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional

19 May, 2022 Egetis Therapeutics raises approximately SEK 180 million through an oversubscribed rights issue News Corporate Action Shares Issuance English Regulatory MAR IR Optional

6 May, 2022 Egetis invites shareholders to an informal information meeting News Corporate Information Other Corporate Information English IR Optional

5 May, 2022 Egetis initiates build-up of medical affairs and the commercial team with the appointment of three senior leaders News Corporate Information Other Corporate Information English IR Optional

28 April, 2022 Egetis Therapeutics publishes prospectus relating to the Rights Issue News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional

26 April, 2022 Interim report January-March 2022 News English Regulatory MAR Report Interim Q1 IR Optional

20 April, 2022 Egetis Therapeutics’ 2021 annual report published News English Regulatory VPML Report Annual IR Optional

13 April, 2022 Bulletin from extraordinary shareholders’ meeting in Egetis Therapeutics AB and publication of timetable relating to the rights issue News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional

Press releases

2022

Calendar and upcoming reports

Contact us

Press releases

2022

Calendar and upcoming reports

Subscribe

Contact us